Multicenter retrospective study of ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma who are refractory or intolerant to platinum-based chemotherapy(WJOG13420G)
Not Applicable
- Conditions
- Gastric or colorectal neuroendocrine carcinoma (NEC)
- Registration Number
- JPRN-UMIN000043200
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of ramucirumab administration before the start of the secondary treatment 2) If the attending physician or study supervising physician determined the case to be unsuitable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression-free survival Response rate Disease control rate Duration of response Adverse event